Sophie Dessureault, MD, PhD

Where You Are:

Sophie Dessureault, MD, PhD



          •  Surgery

          •  H. Lee Moffitt Cancer Center, University of South Florida - Surgical Oncology

          •  University of Toronto, Toronto, Ontario - Surgery

          •  Dalhousie University, Halifax, Nova Scotia - MD

  • Koskan AM, Thomas-Purcell KB, Yu D, Quinn GP, Dessureault S, Shibata D, Jacobsen PB, Gwede CK. Discussion of First-Degree Relatives' Colorectal Cancer Risk: Survivors' Perspectives. Health Commun. 2014 Sep;29(8):782-790. Pubmedid: 24229427.

  • Wong J, Koch AL, Deneve JL, Fulp W, Tanvetyanon T, Dessureault S. Repeat cytoreductive surgery and heated intraperitoneal chemotherapy may offer survival benefit for intraperitoneal mesothelioma: a single institution experience. Ann Surg Oncol. 2014 May;21(5):1480-1486. Pubmedid: 24158467.

  • Morse MA, Niedzwiecki D, Marshall JL, Garrett C, Chang DZ, Aklilu M, Crocenzi TS, Cole DJ, Dessureault S, Hobeika AC, Osada T, Onaitis M, Clary BM, Hsu D, Devi GR, Bulusu A, Annechiarico RP, Chadaram V, Clay TM, Lyerly HK. A randomized phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC1 compared with the same poxvectors plus GM-CSF for resected metastatic colorectal cancer. Ann Surg. 2013 Dec;258(6):879-886. Pubmedid: 23657083. Pmcid: PMC3812363.

  • Kiluk JV, Dessureault S, Quinn G. Teaching medical students how to break bad news with standardized patients. J Cancer Educ. 2012 Jun;27(2):277-280. Pubmedid: 22314793.

  • Kiluk JV, Ly QP, Meade T, Ramos D, Reintgen DS, Dessureault S, Davis M, Shamehdi C, Cox CE. Axillary recurrence rate following negative sentinel node biopsy for invasive breast cancer: long-term follow-up. Ann Surg Oncol. 2011 Dec;18 Suppl 3:339-342. Pubmedid: 19777181.

  • Manne S, Jacobsen PB, Ming ME, Winkel G, Dessureault S, Lessin SR. Tailored versus generic interventions for skin cancer risk reduction for family members of melanoma patients. Health Psychol. 2010 Nov;29(6):583-593. Pubmedid: 21090893. Pmcid: PMC3058834.

  • Bui MM, Draper NL, Dessureault S, Nasir NA, Cooper H, Nasir A, Coppola D. Colonic angiolymphoid hyperplasia with eosinophilia masquerading as malignancy: a case report and review of the literature. Clin Colorectal Cancer. 2010 Jul;9(3):179-182. Pubmedid: 20643624.

  • Desai S, Maurin M, Smith MA, Bolick SC, Dessureault S, Tao J, Sotomayor E, Wright KL. PRDM1 is required for mantle cell lymphoma response to bortezomib. Mol Cancer Res. 2010 Jun;8(6):907-918. Pubmedid: 20530581. Pmcid: PMC2891394.

  • Giglia JL, Antonia SJ, Berk LB, Bruno S, Dessureault S, Finkelstein SE. Systemic therapy for advanced hepatocellular carcinoma: past, present, and future. Cancer Control. 2010 Apr;17(2):120-129. Pubmedid: 20404795.

  • Zhao JJ, Lin J, Lwin T, Yang H, Guo J, Kong W, Dessureault S, Moscinski LC, Rezania D, Dalton WS, Sotomayor E, Tao J, Cheng JQ. microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma. Blood. 2010 Apr;115(13):2630-2639. Pubmedid: 20086245. Pmcid: PMC2852365.

  • Kiluk JV, Ly QP, Santillan AA, Meade T, Ramos D, Reintgen DS, Dessureault S, Davis M, Shamehdi C, Cox CE. Erratum to: Axillary Recurrence Rate Following Negative Sentinel Node Biopsy for Invasive Breast Cancer: Long-Term Follow-Up. Ann Surg Oncol. 2010 Feb;17(2):552-557. Pubmedid: 19957043.

  • Lwin T, Crespo LA, Wu A, Dessureault S, Shu HB, Moscinski LC, Sotomayor E, Dalton WS, Tao J. Lymphoma cell adhesion-induced expression of B cell-activating factor of the TNF family in bone marrow stromal cells protects non-Hodgkin's B lymphoma cells from apoptosis. Leukemia. 2009 Jan;23(1):170-177. Pubmedid: 18843286.

  • Moller M, Lewis J, Dessureault S, Zager J. Toxicities associated with hyperthermic isolated limb perfusion and isolated limb infusion in the treatment of melanoma and sarcoma. Int J Hyperthermia. 2008 May;24(3):275-289. Pubmedid: 18393005.

  • Dessureault S. Ongoing Studies with GM. Cd40L Bystander-Based Vaccines. 2008 Jan;15(4):1255.

  • Lwin T, Hazlehurst LA, Dessureault S, Lai R, Bai W, Sotomayor E, Moscinski LC, Dalton WS, Tao J. Cell adhesion induces p27Kip1-associated cell-cycle arrest through down-regulation of the SCFSkp2 ubiquitin ligase pathway in mantle-cell and other non-Hodgkin B-cell lymphomas. Blood. 2007 Sep;110(5):1631-1638. Pubmedid: 17502456. Pmcid: PMC1975846.

  • Lwin T, Hazlehurst LA, Li Z, Dessureault S, Sotomayor E, Moscinski LC, Dalton WS, Tao J. Bone marrow stromal cells prevent apoptosis of lymphoma cells by upregulation of anti-apoptotic proteins associated with activation of NF-kappaB (RelB/p52) in non-Hodgkin's lymphoma cells. Leukemia. 2007 Jul;21(7):1521-1531. Pubmedid: 17476277.

  • Dessureault S, Noyes D, Lee D, Dunn M, Janssen W, Cantor A, Sotomayor E, Messina J, Antonia S. A phase-I Trial Using a Universal GM-CSF-producing and CD40L-expressing Bystander Cell Line (GM.CD40L) in the Formulation of Autologous Tumor Cell-based Vaccines for Cancer Patients with Stage IV disease. Ann Surg Oncol. 2007 Feb;14(2):869-884. Pubmedid: 17103257.

  • Thompson P, Dessureault S. Tumor cell vaccines. Adv Exp Med Biol. 2007;601:345-355. Pubmedid: 17713023.

  • Dessureault S. Commentary: Evidence-based principles applied to the management of colorectal cancer. Cancer Treat Rev. 2006 Nov;32(7):581-581. Pubmedid: 16884857.

  • Cox C, White L, Allred N, Meyers M, Dickson D, Dupont E, Cantor A, Ly Q, Dessureault S, King J, Nicosia S, Vrcel V, Diaz N. Survival outcomes in node-negative breast cancer patients evaluated with complete axillary node dissection versus sentinel lymph node biopsy. Ann Surg Oncol. 2006 May;13(5):708-711. Pubmedid: 16538416.

  • Azzarello L, Dessureault S, Jacobsen P. Sun-Protective Behavior among Individuals with a Family History of Melanoma. Cancer Epidemiol Biomarkers Prev. 2006 Jan;15(1):142-145. Pubmedid: 16434600.

  • Dessureault S, Alsarraj M, McCarthy S, Hunter T, Noyes D, Lee D, Harkins J, Seigne J, Jennings R, Antonia S. A GM-CSF/CD40L producing cell augments anti-tumor T cell responses. J Surg Res. 2005 May;125(2):173-181. Pubmedid: 15854671.

  • Friberg M, Jennings R, Alsarraj M, Dessureault S, Cantor A, Extermann M, Mellor AL, Munn DH, Antonia SJ. Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection. Int J Cancer. 2002 Sep;101(2):151-155. Pubmedid: 12209992.

  • Kim C, Dessureault S, Gabrilovich D, Reintgen D, Slingluff C. Immunotherapy for melanoma. Cancer Control. 2002;9(1):22-30. Pubmedid: 11907463.

  • Dessureault S, Coppola D, Weitzner M, Powers P, Karl R. Barrett's esophagus and squamous cell carcinoma in a patient with psychogenic vomiting. Int J Gastrointest Cancer. 2002;32(1):57-61. Pubmedid: 12630772.

  • Dessureault S, Soong S, Ross M, Thompson J, Kirkwood J, Gershenwald J, Coit D, McMasters K, Balch C, Reintgen D. Improved staging of node-negative patients with intermediate to thick melanomas (>1 mm) with the use of lymphatic mapping and sentinel lymph node biopsy. Ann Surg Oncol. 2001;8(10):766-770. Pubmedid: 11776489.

  • Dessureault S, Graham F, Gallinger S. Autologous lymphocyte responses to adenovirus-B7-1-transduced human cancer cells. Cancer Gene Therapy. 1999;6(3):195-208. Pubmedid: 10359205.

  • Stewart A, Lassam N, Quirt I, Bailey D, Rotstein L, Krajden M, Dessureault S, Gallinger S, Cappe D, Wan Y, Addison C, Moen R, Gauldie J, Graham F. Adenovector-mediated gene delivery of interleukin-2 in metastatic breast cancer and melanoma: results of a phase 1 clinical trial. Gene Ther. 1999;6:350-363. Pubmedid: 10435085.

  • Prince H, Dessureault S, Gallinger S, Krajden M, Sutherland D, Addison C, Zhang Y, Graham F, Stewart S. Efficient adenoviral-mediated gene expression in malignant human plasma cells: relative lymphoid cell resistance. Exp Hematol. 1998;26:27-36. Pubmedid: 9430511.

  • Lewis J, Zager J, Yu D, Pelaez D, Riker A, Dessureault S, Cruse C, Reintgen D, Puleo C, Sondak V. Full-Thickness Grafts Procured from Skin Overlying the Sentinel Lymph Node Basin; Reconstruction of Primary Cutaneous Malignancy Excision Defects. Ann Surg Oncol. 2008 Jun;15(6):1733-1740. Pubmedid: 18379848.

Dr. Sophie Dessureault is a surgical oncologist in the Department of Gastrointestinal Oncology at Moffitt Cancer Center.  She is an associate professor of oncology and surgery at the University of South Florida College of Medicine.

Dr. Dessureault’s research and clinical interests include cancer vaccines that focus on reversing tumor-induced immune suppression.

Dr. Dessureault graduated with distinction from Dalhousie University School of Medicine in Halifax, Nova Scotia.  After medical school, she pursued additional training at the University of Toronto, where she completed both a surgical residency and a doctorate in the surgical scientist program, where she graduated valedictorian of her.  Dr. Dessureault came to Moffitt in 1999 for a fellowship in a surgical oncology.

Dr. Dessureault has received numerous scholarships and awards, including the Society of Surgical Oncology Young Investigator Award and the American Society of Clinical Oncology Development Award.  In 2008 she was elected to the Barness-Behnke Chapter of the Gold Humanism Honor Society at the University of South Florida.  She was nominated for Moffitt Physician of the Year in 2006, 2008, 2009 and 2010. 

Dr. Dessureault is widely published and is a member of numerous professional organizations, including the American Society of Clinical Oncology, Society of Surgical Oncology, Royal College of Surgeons of Canada and Alpha Omega Alpha Honor Medical Society.

She is fluent in English and French.


TOOLS:   Font Size small font resizer separator font resizer separator big font resizer
 |  Site Map  |  Privacy Policy  |  Terms and Conditions